Brief: Bayer - FDA Priority Review For Sevabertinib
18/05/2026 13:35
May 18 (Reuters) - BAYER AG BAYGn.DE: FDA GRANTS SEVABERTINIB PRIORITY REVIEW AS A FIRST-LINE TREATMENT FOR PATIENTS WITH HER2-MUTANT NON-SMALL CELL LUNG CANCER Further company coverage: [BAYGn.DE] (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 587785269;))
Recent news on Bayer AG
See all newsBayer takes a giant leap toward investability
Europe Research Roundup: Barratt Redrow, Ferrari, KPN
Explainer: What does Bayer's US Supreme Court win mean for the thousands of Roundup lawsuits?
Bayer shares soar over 18% after U.S. Supreme Court curbs Roundup lawsuits
US Supreme Court scales back Roundup cancer suits in win for Bayer (updated)